Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases — Stella

Home/Systemic Lupus Erythematosus (SLE)/A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases

View on ClinicalTrials.gov

Recruiting

Back to Systemic Lupus Erythematosus (SLE) trials

A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

Institute of Hematology & Blood Diseases Hospital, China, Tianjin

Key details

Phase

Early testing

Sponsor

China Immunotech (Beijing) Biotechnology Co., Ltd.

Collaborators

Institute of Hematology & Blood Diseases Hospital, China

Enrollment target

~18 participants

Started

August 2025

Primary completion

August 2026

Age range

18 Years – 65 Years

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.